MENU
About
Overview
Leadership Team
Board of Directors
Investors
Contact Us
Our science
CORRECTx Platform
Scientific Posters & Publications
Pipeline
Partnerships
News
Press Releases
Events & Presentations
News Coverage
Careers
Culture & Values
Competitive Benefits
Current Opportunities
CONTACT US
858.285.4000
info@locanabio.com
share
HOME
NEWS
WORTHY
NEWS
WORTHY
Press Releases
May 19, 2022
Locanabio’s Proprietary CORRECTx
™
RNA-Targeting Gene Therapy Reduces Disease-Causing Hexanucleotide Repeat Expansions in a Model of Amyotrophic Lateral Sclerosis
Oral presentation of new preclinical data at American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting SAN DIEGO, May 19, 2022 – Locanabio, Inc., a genetic medicines company...
READ MORE
May 2, 2022
Locanabio to Present New Preclinical Data Demonstrating Application of CORRECTx™ Platform for Treating Amyotrophic Lateral Sclerosis at American Society of Gene and Cell Therapy 25th Annual Meeting
SAN DIEGO, May 2, 2022 /PRNewswire/ -- Locanabio, Inc., a genetic medicines company developing RNA-targeted therapeutics for patients with severe neuromuscular and neurodegenerative diseases, today...
READ MORE
MORE
January 4, 2022
Locanabio to Present at 40th Annual J.P. Morgan Healthcare Conference
SAN DIEGO, January 4, 2021 – Locanabio, Inc., a genetic medicines company developing therapeutics for patients with severe neuromuscular, neurodegenerative and retinal diseases, today announced...
READ MORE
November 22, 2021
Locanabio to Participate in Upcoming Investor Conferences
SAN DIEGO, November 22, 2021 – Locanabio, Inc., a genetic medicines company developing therapeutics for patients with severe neuromuscular, neurodegenerative and retinal diseases, today announced...
READ MORE
November 18, 2021
Locanabio Presents New Preclinical Data from Myotonic Dystrophy Type 1 Program at Society for Muscle Biology Frontiers in Myogenesis Conference 2021
- New data show allele-specific reduction of CUG repeats and corrected splicing and myotonia in HSALR mice across multiple leads - Company is advancing multiple DM1 leads into non-human primate...
READ MORE
September 7, 2021
Locanabio Expands Leadership Team with Appointment of Kat Lange as Chief Financial Officer
SAN DIEGO, September 7, 2021 – Locanabio, Inc., an RNA-targeting gene therapy company, today announced the appointment of Kat Lange as chief financial officer. In this role, Ms. Lange will be a key...
READ MORE
July 6, 2021
Locanabio Expands Leadership Team with Appointment of Chief Scientific Officer and Chief Medical Officer
SAN DIEGO, July 6, 2021 – Locanabio, Inc., an RNA-targeting gene therapy company focused on developing life-changing therapies for patients with severe neuromuscular, neurodegenerative and retinal...
READ MORE
May 5, 2021
Locanabio Announces Upcoming Preclinical Data Presentations at American Society of Gene and Cell Therapy Annual Meeting
SAN DIEGO, May 5, 2021 – Locanabio, Inc., an RNA-targeting gene therapy company focused on developing life-changing therapies for patients with severe neurodegenerative, neuromuscular and retinal...
READ MORE
DECEMBER 14, 2020
Locanabio Announces $100 Million Series B Financing to Advance Portfolio of Novel RNATargeted Gene Therapies for Neurodegenerative, Neuromuscular and Retinal Diseases
Financing led by Vida Ventures LLC with participation from RA Capital Management, Invus, Acuta Capital Partners, an investment fund associated with SVB Leerink, ARCH Venture Partners, Temasek,...
READ MORE
SEPTEMBER 14, 2020
Treatment with RNA-Targeting Gene Therapy Reverses Molecular and Functional Features of Myotonic Dystrophy Type 1 in Mice
SAN DIEGO, Sept. 14, 2020 /PRNewswire/ -- Locanabio, Inc., a leader in RNA-targeted gene therapy, today announced that results from a preclinical study of the company's therapeutic systems for the...
READ MORE
April 1, 2020
Locana Expands Leadership Team With Appointment of Micah Mackison, as Chief Business Officer
SAN DIEGO, Apr. 1, 2020 – Locana, Inc., a leading RNA-targeting gene therapy company, today announced the appointment of Micah Mackison, as Chief Business Officer. Bringing more than 20 years of...
READ MORE
December 10, 2019
Locana Expands Leadership Team With Appointment of former Casebia CEO, James Burns, Ph.D., as Chief Executive Officer
SAN DIEGO, Dec. 10, 2019 – Locana, Inc., a leading RNA-targeting gene therapy company, today announced the appointment of James Burns, Ph.D., as chief executive officer, as a key step in expanding...
READ MORE
September 23, 2019
Biocom Announces Fourth Annual Catalyst Award Winners
Life science trailblazers under the age of 40 recognized across California SAN DIEGO--(BUSINESS WIRE)--Biocom, the association representing the California life science industry, today announced...
READ MORE
June 12, 2019
MDA Awards Venture Philanthropy Grant to Locana to Develop Novel Treatment for Muscular Dystrophy
NEW YORK and SAN DIEGO – June 12, 2019 – The Muscular Dystrophy Association (MDA) and Locana, a leading RNA-targeting gene therapy company, today announced the award of an MDA Venture...
READ MORE
May 22, 2019
Locana Raises $55 Million Series A Financing to Advance Portfolio of RNA-targeting Gene Therapies
Jeffrey M. Ostrove, Ph.D., named chief executive officer Proprietary technology based on pioneering work from the lab of Eugene (Gene) Yeo, Ph.D. of UC San Diego SAN DIEGO – May 22, 2019 –...
READ MORE
EVENTS & PRESENTATIONS
MAY 19, 2022
Locanabio Presents at ASGCT 25
th
Annual Meeting: AAV9 mediated delivery of RNA targeting systems eliminate hexanucleotide repeat expansions in C9ORF72 ALS/FTD models
READ MORE
DECEMBER 2, 2021
Locanabio CEO presents at the 2021Evercore ISI HealthCONx Conference in Boston
READ MORE
NOVEMBER 21, 2021
Locanabio presents at Piper Sandler 33rd Annual Virtual Healthcare Conference
READ MORE
NOVEMBER 18, 2021
Locanabio Presents Poster at the Society for Muscle Biology’s Frontiers in Myogenesis Conference 2021: AAV9 Mediated Delivery of RNA Targeting Systems Corrects Molecular and Functional Defects in Myotonic Dystrophy Type 1
READ MORE
OCTOBER 8, 2020
Locanabio to Participate in Multiple Upcoming Industry Conferences in Q4 2020
READ MORE
MAY 27, 2020
Locana Participates in the 25th Annual Meeting of the RNA Society to Share Research Regarding RNA-targeting Gene Therapy for Human Genetic Diseases.
READ MORE
MAY 13, 2020
Locana Presents Poster at ASGCT 2020: AAV9 Mediated Delivery of RNA Targeting CRISPR Corrects Molecular and Functional Phenotypes in Myotonic Dystrophy Type 1 Mouse Model
READ MORE
News Coverage
September 23 2020,
ENDPOINTS NEWS
The 20(+1) under 40: Inside the next generation of biotech leaders
READ MORE
September 23 2020,
BIOSPACE
Locanabio’s RNA-Targeting Gene Therapy May Offer Durable Response for DM1 Patients
READ MORE
August 3 2020,
CELL & GENE
The RNA-Targeting Era in Genetic Medicine
READ MORE
July 22 2020,
Biospace
Locanabio’s Combo RNA Modification Platform Targets Multiple RNA Dysfunctions with One Injection
READ MORE
July/August 2020,
DDNews
Q&A: Branching out with RNA-targeting Cas systems
READ MORE
July 11, 2020
Locanabio has been presented an excellence in RNA research RNA SOCIETY Poster Award at RNA 2020 On-line – the 25th Annual Meeting of the RNA SOCIETY
READ MORE
September 23, 2019
Biocom Announces Fourth Annual Catalyst Award Winners
READ MORE
